Novartis Drug Diovan Retains 69% of Prescriptions in U.S.

Novartis AG has held onto 69 percent of Diovan HCT prescriptions in the U.S. since since the heart drug, its best-selling product, lost patent protection in the country last month.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.